NCT05003089View on ClinicalTrials.gov

A Trial to Learn How BAY1834845 and BAY1830839 Affect Inflammation When Taken by Mouth Twice a Day for 7 Days in a Row in Healthy Male Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

51

Participants

Timeline

Start Date

June 28, 2021

Primary Completion Date

December 16, 2021

Study Completion Date

January 20, 2022

Conditions
Immune Mediated Inflammatory Diseases
Interventions
DRUG

BAY1834845

Tablet, oral.

DRUG

BAY1830839

Tablet, oral.

DRUG

Prednisolone

Tablet, oral.

DRUG

Placebo

Tablet, oral.

Trial Locations (1)

2333 CL

Center for Human Drug Research, Leiden

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY